The Prognostic Role of Baseline and Early Dynamics of Peripheral Blood Cell Ratios in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F26%3A10001448" target="_blank" >RIV/00064190:_____/26:10001448 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.21873/invivo.14261" target="_blank" >https://doi.org/10.21873/invivo.14261</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/invivo.14261" target="_blank" >10.21873/invivo.14261</a>
Alternative languages
Result language
angličtina
Original language name
The Prognostic Role of Baseline and Early Dynamics of Peripheral Blood Cell Ratios in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab
Original language description
Background/Aim: Immune checkpoint inhibitors (ICI), including nivolumab, have become the cornerstone of systemic treatment in metastatic renal cell carcinoma (mRCC). Blood-derived biomarkers including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) have emerged as important indicators of systemic inflammatory and immune status. The aim of this study was to evaluate the prognostic and predictive value of NLR, PLR, and LMR at baseline and their early dynamics during nivolumab monotherapy in mRCC patients. Patients and Methods: The associations of baseline NLR, PLR, LMR and their changes (Delta) after one month of nivolumab therapy with patient outcomes including progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) were retrospectively analyzed. Results: In total, 310 patients were included. Baseline NLR >= 4 (PFS: HR=2.136, p<0.001; OS: HR=2.442, p<0.001), PLR >= 310 (PFS: HR=2.383,p<0.001; HR=3.604,p<0.001),and LMR <1.5 (PFS: HR=1.802,p=0.002; OS: HR=2.273,p<0.001) were independent factors for inferior PFS and OS. Regarding early changes, Delta NLR >= 2 (PFS: HR=3.019, p<0.001; OS: HR=3.095, p<0.001) and Delta PLR >= 20 (PFS: HR=1.436, p=0.024; OS: HR=1.719, p=0.006) were independent factors for inferior PFS and OS, while Delta LMR <0 was independent factor for inferior PFS (HR=1.458, p=0.030). Lower ORR was associated with baseline NLR >= 4 (p=0.020), Delta NLR >= 2 (p=0.010), and Delta PLR >= 20 (p=0.019). Conclusion: The results of the present study suggest a prognostic role for baseline NLR, PLR and LMR. In addition, an early change in NLR and PLR is associated with patient outcome and represents a candidate surrogate biomarker for monitoring the immunotherapy response.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2026
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
IN VIVO
ISSN
0258-851X
e-ISSN
1791-7549
Volume of the periodical
40
Issue of the periodical within the volume
2
Country of publishing house
GR - GREECE
Number of pages
15
Pages from-to
1065-1079
UT code for WoS article
001708468900030
EID of the result in the Scopus database
2-s2.0-105031600627